Abstract. To date, there is limited data on the biological effects of low-intensity pulsed ultrasound (LIPUS) on primary malignant bone tumors. The purpose of the present study was to investigate the antitumor effects of LIPUS on osteosarcoma cells. The effects of LIPUS on cell viability, induction of apoptosis, mitochondrial membrane potential and intracellular signaling molecules in the LM8 osteosarcoma cell line were investigated. LIPUS inhibited cell viability (P=0.0022) and mitochondrial membrane potential (P=0.0019) in LM8 cells. Flow cytometry analysis and terminal deoxynucleotidyl transferase dUTP nick end labeling staining revealed significantly higher numbers of apoptotic (P<0.0001) and necrotic cells (P=0.0091) compared with cells without treatment. LIPUS treatment significantly increased phosphorylated Akt (P<0.0001) and IκBα (P=0.0001) levels, and reduced phosphorylated mitogen-activated protein kinase 7 (P<0.0001) and phosphorylated checkpoint kinase 1 (P=0.0008) levels. These results suggest that LIPUS is a non-invasive adjuvant therapy that is able to inhibit cellular proliferation in osteosarcoma cells.
Introduction
Osteosarcoma, which arises from mesenchymal osteoblasts, is the most common malignant bone cancer in children and adolescents (1) . Despite the effective use of chemotherapy (2) and surgical techniques (3) in controlling osteosarcoma, there remains a mortality of rate of ~30%. In addition, patients with unresectable primary tumors or clinically evident metastases have a poor prognosis, even in chemotherapy-responsive cases of osteosarcoma (4, 5) . Therefore, novel effective therapeutic approaches for the treatment of osteosarcoma are required.
Low-intensity pulsed ultrasound (LIPUS) is a non-invasive ultrasound medical technology that uses low-frequency, low-intensity pulses. LIPUS was previously demonstrated to promote bone formation and accelerate bone maturation in cases of bone fracture (6, 7) , distraction osteogenesis (8) and delayed fracture union (9) . LIPUS appears to act by affecting the biological mechanisms of cell proliferation, gene regulation and cell differentiation (10) . Osteosarcoma is characterized by the production of malignant osteoid matrix and differentiation of mesenchymal osteoblasts (11) . LIPUS affects osteoblastic differentiation without increasing the number of osteoblasts (12, 13) . Therefore, the authors hypothesize that LIPUS inhibits osteoblastic differentiation by inducing apoptosis and inhibiting cell growth in osteosarcoma cells. To examine the proposed antitumor effects of LIPUS, cells from the LM8 osteosarcoma cell line were treated with LIPUS, and the effects on cell growth, apoptosis, mitochondrial membrane potential and intracellular signaling molecules were investigated.
Materials and methods
Cells and culture. LM8 mouse osteosarcoma and MC3T3-E1 mouse osteoblastic cells were obtained from the Japanese Collection of Research Bioresources Cell Bank (Ibaraki, Japan) and were maintained in Eagle's minimal essential medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) containing 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37˚C in a humidified incubator containing 5% CO 2 .
Ultrasound apparatus and treatment. The Sonic Accelerated Fracture Healing System ultrasound apparatus (Teijin Ltd., Osaka, Japan) was used with 1.5 MHz frequency pulses, with a pulse width of 200 µs, repeated at 1 kHz, at a spatial average and temporal average intensity of 30 mW/cm, in all sonication experiments. The LIPUS transducer was placed horizontally on each plate of cells for different times (1, 12, 18 or 24 h Apoptosis assay and flow cytometry. LM8 cells (1x10 6 cells/well) were cultured in a 35-mm dish (Lumox dish 35; Sarstedt K.K., Tokyo, Japan) and stimulated with LIPUS at 37˚C for 48 h. The LM8 cells were then treated with trypsin-EDTA, washed with PBS and resuspended in binding buffer (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) according to the manufacturer's protocol. Cell suspension (85 µl) was then incubated with 10 µl Annexin V/fluorescein isothiocyanate and 5 µl protein iodide. After a 15-min incubation at room temperature in the dark, 400 µl binding buffer was added. The cells were analyzed by flow cytometry (FACSCanto II; BD Biosciences, San Jose, CA, USA) and the results were analyzed using software (FlowJo version 10.2; Tomy Digital Biology, Tokyo, Japan).
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay. An Apoptosis
In Situ Detection kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) was used to measure apoptosis using the TUNEL staining method, according to the manufacturer's protocol, following treatment of LM8 (1x10 6 ) cells with LIPUS at 37˚C for 48 h. TUNEL-positive and TUNEL-negative cells were counted in four random high-power fields (magnification, x400) of each section. The rate of apoptosis was calculated using the following equation: TUNEL-positive cell number/total cell number x100 (%).
Screening intracellular apoptosis signaling. LM8 cells were seeded into a 35-mm dish (Lumox dish 35) at a density of 1x10 6 cells. Following incubation overnight at 37˚C, the cells were exposed to LIPUS for 24 or 48 h. The cells were then treated with trypsin-EDTA, rinsed with cold PBS and solubilized in cell lysate buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) containing a complete inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) and 1 mM PMSF (phenylmethyl sulfonyl fluoride; Sigma-Aldrich; Merck KGaA) buffer. Lysates were subsequently rocked gently at 4˚C for 30 min. Following centrifugation at 14,000 x g for 5 min at 4˚C, the supernatants were transferred to test tubes. Sample protein levels were quantified using Bradford method (Protein Assay; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and then diluted to a concentration of 1.0 mg/ml and used with the PathScan Stress and Apoptosis Signaling Antibody Array kit (Cell Signaling Technology, Inc.) according to the manufacturer's protocol. The detected dots were visualized using the supplied LumiGLO reagent and enumerated with the ImageQuant LAS-4000 instrument (GE Healthcare, Chicago, IL, USA). The relative dot densities were determined with ImageJ version 1.48 software (National Institutes of Health, Bethesda, MD, USA), normalized to the relative density of α-tubulin.
Statistical analysis. The significance of differences between groups was evaluated by a paired t-test. Data are presented as the mean ± standard deviation of 6-10 replications performed. In all analyses, P<0.05 was considered to represent a statistically significant difference. All analyses were performed using the Statview statistical software package (version 5.0; Abacus Concepts, Berkley, CA, USA). Analysis of intracellular signaling molecules. As determined with a stress and apoptosis signaling array (Fig. 8) , LIPUS treatment of LM8 cells for 24 h significantly enhanced the levels of phosphorylated (p)-mitogen-activated protein kinase 3/1 (ERK1/2), p-Akt and NF-κB inhibitor α (IκBα; p-ERK1/2 P<0.0001; p-Akt; P<0.0001; IκBα: P<0.0001) and reduced the levels of p-mitogen-activated protein kinase 7 (TAK1) and p-checkpoint kinase 1 (Chk1; TAK1, P<0.0001; Chk1, P= 0.0006). However, there were no effects on the levels of p-Bcl-2-associated agonist of cell death (Bad) (P=0.6926; Fig. 9 ). LIPUS treatment of the LM8 cells for 48 h significantly increased p-Akt and IκBα levels (Akt, P<0.0001; IκBα, P= 0.0001) and reduced p-TAK1 and p-Chk1 levels (p-TAK1, P<0.0001; p-Chk1, P=0.0008). However, there were no effects on the levels of p-ERK1/2 or p-Bad (p-ERK1/2, P=0.2437; Bad, P=0.9837; Fig. 10 ).
Results

Inhibition of cell viability. Treatment with LIPUS for 18 or
Discussion
LIPUS therapy may promote bone formation in cases of fracture (6,7) and accelerate bone maturation in cases of distraction osteogenesis (8) and delayed fracture union (9) by positively affecting all phases of fracture repair (14) , as well as eliciting effects on cyclooxygenase 2 (15,16) and prostaglandins (17,18). There have been several studies reporting that LIPUS has antitumor effects via the induction of apoptosis in cancer cells (19) (20) (21) (22) (23) . For example, LIPUS was previously demonstrated to induce apoptosis by causing membrane damage in human leukemia cells (19) , affecting the Ca 2+ /mitochondrial pathway in human hepatocellular carcinoma cells (23) and enhancing adjuvant chemotherapy in cases of lymphoma (20) . However, there is currently limited data regarding the antitumor effects of LIPUS on osteosarcoma cells, although the treatment of osteosarcoma in children and adolescents remains a serious challenge.
In previous studies, the mechanical stress caused by LIPUS stimulation of osteoblasts was demonstrated to induce the expression of chemokines and the receptors of nuclear factor κB ligand, Figure 8 . Representative image of a stress and apoptosis signaling protein array following the treatment of LM8 cells with or without low-intensity pulsed ultrasound for 48 h. X, blank spot; p-, phosphorylated; ERK, mitogen-activated protein kinase; MAPK, mitogen-activated protein kinase; SAPK/JNK, mitogen-activated protein kinase 8; IκBα, NFκB inhibitor α; eIF2α, eukaryotic translation initiation factor 2α; TAK1, mitogen-activated protein kinase 7; Chk1, checkpoint kinase 1; Bad, Bcl-2-associated agonist of cell death. Figure 9 . Effects on comprehensive intracellular signaling following LIPUS treatment for 24 h. LM8 cells were treated with LIPUS for 24 h, resulting in a significant increase in p-ERK1/2, p-Akt, and IκBα levels (p-ERK1/2, P<0.0001; p-Akt, P<0.0001; IκBα, P<0.0001) and a decrease in p-TAK1 and p-Chk1 levels (p-TAK1, P<0.0001; p-Chk1, P= 0.0006). There was no effect on p-Bad levels (P= 0.6926). LIPUS, low-intensity pulsed ultrasound; ERK1/2, mitogen-activated protein kinase 3/1; IκBα, NFκB inhibitor α; TAK1, mitogen-activated protein kinase 7; Chk1, checkpoint kinase 1; Bad, Bcl-2-associated agonist of cell death. Figure 10 . Effects on intracellular signaling following LIPUS treatment for 48 h. LM8 cells were treated with LIPUS for 48 h, resulting in a significant increase in p-Akt and IκBα levels (p-Akt, P<0.0001; IκBα, P=0.0001) and a decrease in p-TAK1 and p-Chk1 levels (p-TAK1, P<0.0001; p-Chk1, P= 0.0008). There were no effects on p-ERK1/2 or p-Bad levels (p-ERK1/2, P= 0.2437; Bad, P= 0.9837). LIPUS, low-intensity pulsed ultrasound; IκBα, NFκB inhibitor α; TAK1, mitogen-activated protein kinase 7; Chk1, checkpoint kinase 1; ERK, mitogen-activated protein kinase; Bad, Bcl-2-associated agonist of cell death.
an essential osteoblast differentiation factor (12) . Furthermore, LIPUS stimulates the ability of osteoblasts to differentiate, mature and form bone, with elevated bone sialoprotein expression observed during late osteoblast differentiation (13) . As osteosarcoma is characterized by malignant osteoblastic differentiation and osteoid matrix production (11), cell growth was investigated in the present study to determine whether LIPUS may be used to inhibit osteosarcoma cell growth. The results revealed that treatment with LIPUS for 18 or 24 h (P=0.0133 and P=0.0022, respectively) significantly inhibited LM8 cell growth, whereas no effects were observed on MC3T3-E1 cell growth at the same time points. Additionally, the LM8 cells undergoing LIPUS treatment for 48 h exhibited a significantly lower mitochondrial membrane potential compared with untreated cells (P= 0.0019), whereas no significant effects were observed in the MC3T3-E1 cells, with or without treatment. These results indicate that mechanical stimulation of osteosarcoma cells by LIPUS damages intracellular mitochondria, decreases mitochondrial membrane potential and inhibits viability. In addition, flow cytometry analysis revealed that LM8 cells subjected to LIPUS treatment had significantly higher numbers of apoptotic and necrotic cells compared with untreated cells (apoptotic cells, P<0.0001; necrotic cells, P= 0.0091), and TUNEL staining analysis demonstrated that LM8 cells treated with LIPUS had significantly higher numbers of apoptotic cells compared with cells without treatment (P<0.0001). These results demonstrate that LIPUS treatment effectively inhibits cell viability and induces apoptosis in osteosarcoma cells.
Previous reports have revealed that LIPUS stimulated the phosphorylation of ERK1/2 and Akt in osteosarcoma cell lines (21) as well as the activation of ERK1/2 in osteosarcoma cells, which have been induced to undergo apoptosis and autophagy (24) . In addition, Akt may induce apoptosis via inhibition of Chk1 (25) . In the present study, the levels of p-ERK1/2 and p-Akt were increased and the level of p-Chk1 was decreased in apoptotic LM8 cells following LIPUS treatment.
TAK1, a common upstream regulator of NF-κB, prevents apoptosis via NF-κB-induced downregulation of IκBα (26, 27) . This mechanism may partially explain why LIPUS treatment significantly reduced the levels of p-TAK1 (P<0.0001) and enhanced the levels of IκBα (P=0.0001) as a result of the induction of apoptosis in LM8 cells.
The use of adjuvant chemotherapy has proven effective in osteosarcoma (2, 4) . Despite treatment advances and significant improvements in survival rate, the prognosis for patients with osteosarcoma remains poor (4). To improve the prognosis of patients with osteosarcoma, it is necessary to develop novel effective adjuvant treatments. LIPUS, in combination with chemotherapy or radiation, is a promising therapy for osteosarcoma patients.
In conclusion, it has been demonstrated that LIPUS treatment may effectively inhibits cell growth and induces apoptosis in osteosarcoma cells. As a non-invasive approach, LIPUS promises a range of clinical advantages, including brief, targeted applications to the tumor site.
